Poor correlation has been reported between the Roche Cobas AmpliPrep/Cobas (TaqMan) HIV-1 TaqMan assay and the Roche Cobas Amplicor HIV-1 Monitor version 1.5 Amplicor assay. We report 8 patients who experienced unexplained detectable viremia, despite exemplary medication adherence, following a change in viral quantification assay from Amplicor to TaqMan in January 2008. All patients were found to have undetectable HIV RNA by branched DNA (bDNA) assay.
T he primary goal of antiretroviral therapy (ART) in treatment-naive as well as -experienced patients is to maintain maximal and sustained suppression in plasma HIV RNA levels below the assay limit of detection. 1 Poor correlation has been reported between the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 (TaqMan) assay and the previously widely used Roche Cobas Amplicor HIV-1 Monitor version 1.5 (Amplicor) assay. 2, 3 After the introduction of the TaqMan assay at our center in January 2008, we have observed an increase in detectable viremia among patients who previously had undetectable viral load levels. 2, 3 We report 8 patients who experienced unexplained detectable viremia following a change in viral quantification assay from Amplicor to TaqMan in January 2008.
Case 1
A 58-year-old female was initiated on ART in April 2005. The patient was virologically suppressed until October 2007, when 2 consecutive viral loads of 70 and 50 copies/mL, respectively, were detected. Over the next 13 months, the patient, who was also a peer educator, became increasingly distressed by persistently elevated viral load levels despite maintaining strict medication adherence. Investigation of viral resistance with genotypic assays yielded no significant mutations. In February 2009, the patient's viral load was measured by branched DNA (bDNA) assay and was found to be undetectable with <75 copies/mL. The same specimen yielded a viral load of 3500 copies/ mL by TaqMan.
Case 2
A 45-year-old male was initiated on ART in April 2006. For the next 2 years, the patient was virologically suppressed except for periodic increases or ''blips'' in viral load despite excellent medication adherence. In June 2009, the patient's viral load was measured by bDNA assay and was found to be <75 copies/mL. A specimen collected 19 days earlier yielded a viral load of 58 copies/mL by TaqMan.
Case 3
A 48-year-old male was initiated on ART in July 2006. The patient was virologically suppressed until July 2008 when HIV viral loads became detectable. In March 2009, the patient's viral load was measured by bDNA and was found to be <75 copies/mL. This same specimen of blood yielded a viral load of 150 copies/mL by TaqMan.
Case 4
A 44-year-old male was initiated on ART in May 2006. The patient was virologically suppressed until May 2008, when HIV viral loads became detectable. Investigation of viral resistance with a genotypic assay yielded no significant mutations. All specimen of blood following May 2008 were also detectable, until in September 2009, the viral load was measured by bDNA and was found to be <75 copies/mL.
Case 5
A 50-year-old male was initiated on his current ART regimen in February 2005. In September 2009, the patient's viral load was measured by bDNA and was found to be <75 copies/ml. A specimen collected 14 days earlier yielded a viral load of 1200 copies/mL by TaqMan.
Case 6
A 47-year-old male was initiated on his current ART regimen in December of 2004. Investigation of viral resistance with a genotypic assay yielded no significant mutations. In October 2009, the patient's viral load was measured by bDNA assay and was found to be undetectable with <75 copies/mL. The same specimen yielded a viral load of 1170 copies/mL by TaqMan.
Case 7
A 40-year-old male was initiated on his current ART regimen in June 2006. Investigation of viral resistance with a genotypic assay yielded no significant mutations. In October 2009, the patient's viral load was measured by bDNA and was found to be <75 copies/mL. The same specimen yielded a viral load of 4110 copies/mL by TaqMan.
Case 8
A 47-year-old male was initiated on his current ART regimen in November 2008. The patient's viral load never became undetectable, despite maintaining strict medication adherence and directly observed therapy. All specimens of blood were detectable by TaqMan until in November 2009, the viral load was measured by bDNA and was found to be <75 copies/mL.
Discussion
These cases illustrate what has been documented in clinical practice yet sparsely reported in the medical literature following the widespread use of TaqMan for HIV viral load measurements. We became concerned when we observed patients whose viral load was consistently undetectable developing viremia without an obvious explanation. None of the patients described above had experienced an intercurrent illness or received vaccinations within 4 weeks of documented viremia. To ascertain adherence, the patients were evaluated by a clinical pharmacist as part of an ongoing long-term adherence project piloted at our center. 4 The absence of obvious causes served as the impetus to measure HIV viral loads by an alternative method (ie, bDNA). Further strengthening the case for spurious results by TaqMan assay is that plasma samples were simultaneously analyzed by TaqMan and bDNA methodology in 3 of the cases. Any obvious explanations for detectable viremia with TaqMan would likely be reflected in the bDNA assay as well.
The clinical consequences of low-level viremia, whether transient or persistent, remain largely unknown. However, as we previously reported, spurious viral load measurements can lead to increased anxiety among patients as well as health care providers and increased utilization of resources. 5 Indeed, the cases above reveal the unnecessary burden of additional viral load measurements as well as genotypic resistance assays drawn in response to persistently detectable viremia ( Table 1 ). In fact, the magnitude of viremia in several instances exceeded the commonly accepted threshold of viral load blips. HIV treatment guidelines emphasize the importance of the achievement and maintenance of undetectable viral loads in all patients. Because one of the principal performance measures for HIV treatment programs includes documenting the proportion of patients on ART with undetectable viremia, then redefining the thresholds for viral load assays may be necessary.
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